Compare PD & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PD | RLAY |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 4.1B |
| IPO Year | 2019 | 2020 |
| Metric | PD | RLAY |
|---|---|---|
| Price | $14.45 | $17.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | $12.63 | ★ $19.50 |
| AVG Volume (30 Days) | 1.6M | ★ 3.0M |
| Earning Date | 05-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 416.95 | 31.78 |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $492,546,000.00 | $15,355,000.00 |
| Revenue This Year | $3.58 | N/A |
| Revenue Next Year | $2.88 | $324.03 |
| P/E Ratio | $78.68 | ★ N/A |
| Revenue Growth | 5.36 | ★ 53.44 |
| 52 Week Low | $5.70 | $5.01 |
| 52 Week High | $16.91 | $21.27 |
| Indicator | PD | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 59.96 | 38.54 |
| Support Level | $12.78 | $11.68 |
| Resistance Level | $14.67 | $20.29 |
| Average True Range (ATR) | 0.51 | 0.85 |
| MACD | -0.05 | -0.13 |
| Stochastic Oscillator | 70.83 | 13.77 |
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the company derives a majority of its revenue from the United States and the rest from International markets.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.